Neurofibromatosis type 1 is an autosomal dominant disorder caused by loss-of-function mutations in the
NF1
gene, leading to constitutive Ras pathway activation.
NF1
gene mutations exhibit complete penetrance, cause high phenotypic variability, and feature diverse types without established hotspots. This study identified a novel pathogenic variant via whole-exome sequencing in a pediatric case, broadening the spectrum of known
NF1
mutations. We further describe the clinical response to the MEK inhibitor selumetinib, including regression of subcutaneous nodules, with no significant improvement in cutaneous neurofibroma scores was observed.